Panel Questions and Discussion (13of33) Quality – Oct. 16-17, 2019

FDA Expert Panel on Food Allergies

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Direct: Combating Rare Diseases at the FDA

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

Roundtable on PMTA Submissions for ENDS Products

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

FDA’s Rare Disease Day 2026 – An Event for Patients

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting

2025 FDA Achievements

FDA Celebrates 120 Years